What we know about a new health data tracking system being announced by White House
The collaboration between the federal government and Big Tech would allow patients to more seamlessly track and share their medical records or data among doctors, hospital systems and health apps, the administration and participating companies say.
More details of the system are expected to be announced during a White House event dubbed 'Making Health Technology Great Again' later Wednesday.
Here's how it would work
The system would be maintained by the federal government through the Centers for Medicare and Medicaid Services. Patients will need to opt in to have their medical records and data shared, which CMS says will be kept secure.
Once a patient is in the system, their information could be shared across apps or health systems that have joined the initiative. So, for example, the Apple Health app on your iPhone that tracks your daily step count or your sleep could access lab results from your doctor's office. Putting that information together, the Trump administration says, will offer a fuller picture of your health.
The program could start next year
The U.S. Department of Health and Human Services says that 60 companies have signed on to work with the system and that they have pledged to 'deliver results to the American people in the first quarter of 2026.'
Patient privacy is a top concern
Patient advocates and ethicists say many may worry about how their health information – something Americans have long carefully guarded – could be used in ways that they don't want or expect.
'There are enormous ethical and legal concerns,' said Lawrence Gostin, a Georgetown University law professor who specializes in public health. 'Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families.'
Also, digital privacy advocates say are skeptical that patients will be able to count on their data being stored securely.
'This scheme is an open door for the further use and monetization of sensitive and personal health information,' said Jeffrey Chester at the Center for Digital Democracy.
Amanda Seitz, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif., August 06, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx," said John Hanna, CEO of CareDx. "His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase." In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. "On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO," said John Hanna. "Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best." About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts CareDx Media Contacts Natasha Moshirian Wagnernwagner@ Investor RelationsCaroline Cornerinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Ontario, medical association near new compensation deal they say will help retain, recruit family doctors
The Ontario government and the Ontario Medical Association (OMA) say they're close to reaching a new compensation deal for doctors working in family health organizations, which is intended to draw more physicians to family medicine amid a provincial doctor shortage. Both parties say the proposed changes, which would impact roughly 6,500 family physicians, are intended to encourage more doctors to practice or remain in comprehensive family medicine. Negotiations are happening as more than two million Ontarians are without a family doctor. The new model, called FHO+, would allow doctors to bill for administrative tasks that are currently unpaid, on top of clinical tasks, according to the OMA. The Ontario College of Family Physicians says in an average week, doctors spend about 19 hours on administrative tasks, such as filling out forms, charting and reviewing test results. An OMA spokesperson said in an email that the new compensation model "recognizes family physicians are treating patients with increasingly complex conditions, which often require physicians to spend more time completing administrative tasks." "We believe allowing family physicians to bill for this larger administrative workload will attract and retain more of them in Ontario," Julia Costanzo said in the emailed statement. "Our hope is that this new model will enable more Ontarians to [be] able access a family doctor." WATCH | Breaking down Ontario's family doctor shortage: The FHO+ model will also end "negation," the OMA statement said, the practice of financially penalizing a family doctor when a patient of theirs who is part of a family health team goes to a walk-in clinic or an emergency department for non-emergency care. The proposed deal would update the current compensation model, which pays doctors working in the province's 615 family health organizations through capitation. While different doctors are compensated in different ways, most family doctors get an annual payment from the government for every patient on their roster, with payments adjusted for factors like age and patient complexity. Bachir Tazkarji, a family physician and medical director of the teaching unit at Summerville Family Health Team, says he thinks the new deal would make comprehensive family medicine a bigger draw for new doctors. "Physicians are staying away from comprehensive family medicine practice, because they have less compensation, where, if they're working in hospitals or O.R., for example, they get compensated for more of this work," he said, adding that about 15 to 35 per cent of his month is spent doing administrative work. "I would think this [deal] is going to be very attractive and helpful to physicians for a better quality of life, reducing burnout and improving the patient's care, improving the direct contact with patients," he said. Health Minister Sylvia Jones told reporters at an unrelated news conference Wednesday that she would not comment on the details of negotiations with OMA, but that talks have been generally positive. A spokesperson for the Ministry of Health said in an email that the "FHO+ model incentivizes enrolling new patients, promotes shifting procedures to clinics instead of emergency departments, and strengthens incentives for after-hours care to expand access." The proposed deal was sent to arbitration in June, with a ruling expected in the fall. OMA CEO Kimberly Moran says the deal is about 90 per cent agreed upon and would be in place in April 2026 if finalized. She told CBC Radio's Here and Now Wednesday that while it's important doctors are compensated for "the really large and alarming amount of clinical administration time that they're spending," the province also needs to support physicians with teams and artificial intelligence tools that will reduce the work in the first place. "They didn't go to medical school [to be] on their computer. They went to medical school because they like to treat patients," she said. The Ford government has promised to connect every Ontarian to a family doctor or primary care team by 2029.
Yahoo
11 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
